- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07951242
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of a Children's Fiber Blend on Digestive Health and Gut Microbiome Composition in Children
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LOAM Kids Gut Starter Fiber Formula on Digestive Health and Gut Microbiome Composition in Children
This study evaluates the impact of a fiber blend supplement on gastrointestinal symptoms and the gut microbiome in children aged 3-6 with a history or irregular stooling.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Bryce Jarman
- Telefonnummer: 323-325-1327
- E-Mail: bryce@loamscience.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female child, aged 3-6 years (inclusive) at the time of enrollment.
- Caregiver reports the child consumes few vegetables, whole fruit, whole grains, or legumes per week (fewer than two per day on average), consistent with this study's operational definition of low dietary fiber intake.
- Caregiver reports infrequent or difficult bowel movements (constipation) in the child over the past four weeks
- Caregiver reports the child has experienced excess gas, or bloating, over the past four weeks
- Caregiver is willing and able to administer the study product to the child once daily with a meal for 4 weeks, complete digital questionnaires at Baseline, Weeks 1, 2, 3, and End of Study on behalf of the enrolled child, and to facilitate at-home microbiome stool sample collection at Baseline and End of Study and return samples per provided instructions.
- Child is generally healthy, without any acute or chronic condition that would preclude safe participation as determined by caregiver report.
- Caregiver is willing to maintain the child's current diet, sleep patterns, and activity levels throughout the study duration, and to avoid introducing new fiber supplements or probiotic/prebiotic products during the study period.
- Caregiver and child reside in the United States.
- Caregiver is willing and able to provide informed consent; child assent will be obtained where age-appropriate and consistent with IRB requirements.
Exclusion Criteria:
- Known milk allergy, dairy allergy, lactose intolerance, or any known sensitivity to milk-derived products. (The study product's active formulation contains a milk allergen.)
- Child is currently breastfeeding.
- Known allergy or sensitivity to any component of the study product.
- Currently receiving anticoagulant or antiplatelet medications (e.g., warfarin), due to potential interaction with Vitamin K2 contained in the study product.
- Diagnosis of, or current treatment for, any gastrointestinal disease or disorder, including but not limited to: inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac disease, or diagnosed functional gastrointestinal disorders requiring medical management.
- Use of any prescription or over-the-counter laxative, stool softener, antidiarrheal medication, or fiber supplement on a regular basis (≥3 times per week) in the 4 weeks prior to enrollment, or intent to use during the study.
- Use of oral antibiotics or antifungals within 4 weeks prior to enrollment, or anticipated use during the study period.
- Use of any probiotic or prebiotic supplement (other than those naturally occurring in diet) in the 4 weeks prior to enrollment, or intent to use during the study.
- Significant acute illness, including fever, acute gastrointestinal infection, or other acute medical condition at the time of enrollment, or any chronic medical condition, developmental condition, or disability that, in the caregiver's judgment or per clinical guidance, would prevent the child from safely adhering to the study protocol.
- Any planned surgical procedure during the 4-week study period.
- Participation in another research study currently or within the past 30 days, or planned participation in any other research study during this study's duration.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
Color and taste matched placebo. |
|
Experimental: Fiber Blend
|
This fiber blend contains a blend of Bifidogenic fibers and HMOs |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Stool Frequency
Zeitfenster: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported number of bowel movements per week |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Stool Consistency
Zeitfenster: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Caregiver reported stool consistency using the pediatric-adapted Bristol Stool Scale (one-seven, with one indicating hard lumpy stools and seven indicating soft liquid stools) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
|
Digestive Comfort
Zeitfenster: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Digestive comfort assessed using a visual analog scale (one-five, with one being very bad and five being very good) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Microbiome Composition
Zeitfenster: Baseline, End of Study (Week 4)
|
Determined using shotgun metagenomic sequencing |
Baseline, End of Study (Week 4)
|
|
Gas and Bloating
Zeitfenster: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Gas and bloating assessed using a visual analog scale (one-five, with one being never bloated and five being always bloated) |
Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- LOA005
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Data is proprietary
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .